Related Experiment Video
Updated: Oct 13, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Oral tegafur in the treatment of metastatic breast cancer: a phase II study
M J Kajanti1, S O Pyrhönen, A G Maiche
1Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Abstract:
Between February 1985 and October 1989, 26 patients previously treated for metastatic breast cancer received oral tegafur, at a median daily dose of 1200 mg. Of these, 21 were evaluable for response. The overall response rate was 29%; six (two in lungs, two in skin and two in lymph nodes) of 44 evaluable lesions (14%) responded to therapy. Haematological toxicity was mild, and no other dose-limiting toxicity was seen. The data indicate some activity in heavily pretreated metastatic breast cancer even after previous 5-FU therapy.

